Evidence map›Paper›PMID 24272702›Full record

ReviewGlia2014

The role of astrocytes in mediating exogenous cell-based restorative therapy for stroke.

Yi Li, Zhongwu Liu, Hongqi Xin, Michael Chopp

Abstract readReview
In one paragraph

Review in Glia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Editorial: The role of astrocytes in stroke.Frontiers in cellular neuroscience · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Targeting GABABrain sciences · 2021
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi LiDepartment of Neurology, Henry Ford Hospital, Detroit, Michigan.
Zhongwu Liu
Hongqi Xin
Michael Chopp

Funding

miR-17-92 exosome treatment of strokeR01NS088656 · NINDS · HENRY FORD HEALTH SYSTEM · PI CHOPP, MICHAEL · 2015 to 2019
$1.6M
tPA, white matter and cell therapy for strokeR01NS066041 · NINDS · HENRY FORD HEALTH SYSTEM · PI LIU, ZHONGWU · 2010 to 2014
$1.6M
MSCs Induce Brain Plasticity via tPAR01AG037506 · NIA · HENRY FORD HEALTH SYSTEM · PI CHOPP, MICHAEL · 2011 to 2015
$1.5M
NIA NIH HHS R01 AG037506NIA NIH HHS R01AG037506NINDS NIH HHS R01 NS066041NINDS NIH HHS R01NS066041NINDS NIH HHS R01 NS088656
6 · The paper itself

Abstract

Astrocytes have not been a major therapeutic target for the treatment of stroke, with most research emphasis on the neuron. Given the essential role that astrocytes play in maintaining physiological function of the central nervous system and the very rapid and sensitive reaction astrocytes have in response to cerebral injury or ischemic insult, we propose to replace the neurocentric view for treatment with a more nuanced astrocytic centered approach. In addition, after decades of effort in attempting to develop neuroprotective therapies, which target reduction of the ischemic lesion, there are no effective clinical treatments for stroke, aside from thrombolysis with tissue plasminogen activator, which is used in a small minority of patients. A more promising therapeutic approach, which may affect nearly all stroke patients, may be in promoting endogenous restorative mechanisms, which enhance neurological recovery. A focus of efforts in stimulating recovery post stroke is the use of exogenously administered cells. The present review focuses on the role of the astrocyte in mediating the brain network, brain plasticity, and neurological recovery post stroke. As a model to describe the interaction of a restorative cell-based therapy with astrocytes, which drives recovery from stroke, we specifically highlight the subacute treatment of stroke with multipotent mesenchymal stromal cell therapy.

Indexed as

Cell- and Tissue-Based TherapyAnimalsAstrocytesHumansStrokeexosomesmarrow stromal cellsmicroRNAplasticityrestorationShhstroketPA

Identifiers

PMID24272702
PMCPMC3947888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.